Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

"Based on our investigation, we believe that Oxbryta carries unreasonable and unwarned risks to its users. We are proud of all of the SCD patients who have stepped forward to provide assistance in ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer in September recalled the sickle cell anemia treatment Oxbryta due to safety concerns. The drug was gained in the 2022 purchase of Global Blood Therapeutics Inc. for $5.4 billion.